Article Details

Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for ...

Retrieved on: 2021-02-24 22:52:30

Tags for this article:

Click the tags to see associated articles and topics

Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for .... View article details on hiswai:

Excerpt

Debiopharm has developed several proprietary ADC technology platforms, Multilink™ a cleavable linker-drug -platform enabling high drug-to-antibody ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up